Close
Interdisciplinary project wins £50k from EPSRC & MRC
1 December 2022
Dr Beattie Melinek, Prof Dan Bracewell and Dr Rajvinder Kardan, have been awarded funding from the EPSRC & MRC Impact Acceleration Account for "In vivo demonstration of platform pDNA production and delivery technologies for the treatment of rare genetic diseases”
Congratulations to Beattie for her award of £50,500 (total value £ 127,651 including staffing costs covered by FTHM/UCL) for a 12 month project starting in January. The research will take place from within the FTHM Hub and is jointly funded by UCL’s EPSRC & MRC Impact Acceleration Accounts (IAAs) under TAS call 9.
Dr Beatrice Melinek:
Cell and Gene therapies are potentially transformative treatments that teach our bodies how to make important proteins that can save our sight, mobility, even life. At the heart of these therapies is the key ingredient DNA. But does it matter how this DNA is made? We think it is likely. And together with Dr Rajvinder Karda from the Institute for Women’s Health, Professor Daniel Bracewell and I from UCL Biochemical Engineering will be conducting an interdisciplinary study to answer that question.
Links:
- Translational funding opportunities at UCL
- Dr Ravjinder Kardan's profile
- Prof. Dan Bracewell's profile
- Dr Beatrice Melinek's profile